Rhythm Pharmaceuticals Stock (NASDAQ: RYTM)

Rhythm Pharmaceuticals

RHYTHM PHARMACEUTICALS INC

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Doctor,Measuring,Obese,Man,Waist,Body,Fat.,Obesity,And,Weight

Analyst Color

Biotech

Equities

News

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

RYTM

Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion

Rhythm Pharmaceuticals&#39; Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

jim-cramer_shutterstock2

ASPN

ENVX

LRCX

MRVL

VALE

The &#34;Mad Money&#34; host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.

Jim Cramer Is &#39;Willing To Let This Pharma Stock Catch Fire,&#39; Advises Not To Sell McKesson

Markets

During the R&amp;D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin recep

Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma&#39;s Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals Inc

Press Releases

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Earnings

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Amicus Therapeutics

Grifols, S.A. - American Depositary Shares

Grifols

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Metsera

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Comments

Rhythm Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga